Alzheimer's biomarker and neuroimaging initiative (ADNI4)
Official title: Alzheimer's Disease Neuroimaging Initiative (ADNI4)
Funded at Northern California Institute/res/edu · NIH-11386830 · Data updated 2026-11-12
This project collects brain scans, blood and other samples from people with and without memory problems to improve tests that detect and track Alzheimer’s and to include more diverse participants in research.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northern California Institute/res/edu NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 30, 2004 |
| Project end | July 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $58,957 |
| NIH project number | 3U19AG024904-18S4 |
| Project ID | NIH-11386830 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include people with memory concerns, early cognitive symptoms, diagnosed mild cognitive impairment or Alzheimer’s, and also cognitively normal volunteers including those from underrepresented racial and ethnic groups.
✕Less likely to help
People seeking an immediate therapeutic benefit or those unwilling/unable to attend repeated visits or undergo scans, blood draws, or lumbar puncture may not personally benefit from participation.
What this research studies
If you join, you may have brain imaging, blood draws, cognitive testing, and possibly cerebrospinal fluid collection at scheduled visits over time, with your data and samples stored in shared repositories. The team will follow hundreds of prior ADNI participants and recruit additional volunteers, with a strong focus on including people from underrepresented communities. Researchers will use the clinical, imaging, genetic, and fluid data to refine biomarkers (including new blood tests) that can identify Alzheimer’s changes earlier and make clinical trials more reliable. The project shares data widely so discoveries can speed development of future treatments.
Why it matters
Potential benefit: If successful, this work could lead to better blood and imaging tests that detect Alzheimer’s earlier and make clinical trials faster and more accurate, benefiting future patients.
How similar studies have gone: Earlier ADNI phases and similar large biomarker consortia have produced thousands of publications and directly informed clinical trial design, showing a strong track record for this approach.
Where this research is happening
-
Northern California Institute/res/edu
San Francisco, United States Active
Researchers
- Principal investigator: Weiner, Michael W — Northern California Institute/res/edu
- Study coordinator: Weiner, Michael W
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.